Theratechnologies (TSX:TH) Total Equity : C$-35.3 Mil (As of Nov. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Theratechnologies Total Equity?

Theratechnologies's total equity for the quarter that ended in Nov. 2024 was C$-35.3 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Theratechnologies Total Equity Historical Data

The historical data trend for Theratechnologies's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies Total Equity Chart

Theratechnologies Annual Data

Trend

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Nov24

Total Equity

Get a 7-Day Free Trial

4.22

22.32

-30.37

-28.61

-35.31

Theratechnologies Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
Total Equity	Get a 7-Day Free Trial															-28.61	-33.21	-31.72	-26.87	-35.31

Theratechnologies Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Theratechnologies's Total Equity for the fiscal year that ended in Nov. 2024 is calculated as

Total Equity	=	Total Assets(Q: Nov. 2024 )	-	Total Liabilities(Q: Nov. 2024 )
	=	74.532	-	109.845
	=	-35.3

Theratechnologies's Total Equity for the quarter that ended in Nov. 2024 is calculated as

Total Equity	=	Total Assets(Q: Nov. 2024 )	-	Total Liabilities(Q: Nov. 2024 )
	=	74.532	-	109.845
	=	-35.3

Theratechnologies Total Equity Related Terms

Thank you for viewing the detailed overview of Theratechnologies's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Theratechnologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (TSX:TH) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

THTX:USA TQ80:Germany TQ80:Germany

Address

2015, rue Peel, 11th Floor, Montreal, QC, CAN, H3A 1T8

Website

https://www.theratech.com

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.

Executives

Dale Weil	Director
Joseph Arena	Director
Philippe Dubuc	Senior Officer
Gérald A. Lacoste	Director
Paul Lévesque	Senior Officer
Andrew Molson	Director
Dawn Svoronos	Director
John Leasure	Senior Officer
Alain Trudeau	Director
Sheila Frame	Director
Gary Peter Littlejohn	Director
Marie-noël Colussi	Senior Officer
Jovan Antunovic	Senior Officer
Christian Marsolais	Senior Officer
Jocelyn Lafond	Senior Officer